New combo therapy aims to stop liver cancer return in High-Risk patients
NCT ID NCT07160361
First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 30 times
Summary
This study tests a new two-drug approach for liver cancer patients whose tumors show 'tumor budding,' a sign of high recurrence risk. After surgery, participants receive a collagen-degrading drug plus a targeted therapy to help drugs reach cancer cells and kill them. The goal is to see if this combination lowers the chance of cancer coming back within two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.